title: Gene therapy for epilepsy.
abstract: Gene therapy may represent an effective alternative to standard pharmacological approaches for certain forms of epilepsy. Currently, the best candidates for this therapeutic approach appear to be epilepsies characterized by a focal lesion. Gene therapy has been attempted to produce antiepileptogenic (prevention of development of epilepsy in subject at risk after having received an epileptogenic insult), antiseizure (reduction of frequency and/or severity of seizures), and disease-modifying (alteration of the natural history of the disease) effects. An example of gene therapy aimed at producing antiepileptogenic effects is a combination therapy based on the supplementation of the neurotrophic factors brain-derived neurotrophic factor (BDNF) and fibroblast growth factor 2 (FGF-2). Antiseizure effects have been obtained by increasing the strength of inhibitory signals (by supplementing specific GABAA receptor subunits or inhibitory neuropeptides like galanin or neuropeptide Y) or by reducing the strength of excitatory signals (by knocking down NMDA receptor subunits). This review summarizes the results obtained to date using gene therapy in epilepsy models and discusses the challenges and the opportunities that this approach can offer for the treatment of human epilepsies.
authors.affiliation: Department of Medical Sciences, Section of Pharmacology and Neuroscience Center, University of Ferrara, Italy; National Institute of Neuroscience, University of Ferrara, Italy; Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Italy. Electronic address: michele.simonato@unife.it.
authors.forename: Michele
authors.initials: M
authors.lastname: Simonato
mesh_terms: D000818:Animals; D019208:Brain-Derived Neurotrophic Factor / Q000235:genetics / Q000627:therapeutic use*; D004827:Epilepsy / Q000628:therapy*; D016222:Fibroblast Growth Factor 2 / Q000235:genetics / Q000627:therapeutic use*; D019004:Galanin / Q000235:genetics / Q000627:therapeutic use*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D009478:Neuropeptide Y / Q000627:therapeutic use*
chemical_list: D019208:Brain-Derived Neurotrophic Factor; D009478:Neuropeptide Y; D016222:Fibroblast Growth Factor 2; D019004:Galanin
keywords: Brain-derived neurotrophic factor; Epileptogenesis; Galanin; Neuropeptide Y; Seizures; Viral vectors